110 related articles for article (PubMed ID: 25557692)
1. Investigation of an anti-activated factor X (anti-Xa) assay for the quantification of enoxaparin in human plasma.
Al-Sallami HS; Medlicott NJ
J Pharm Pharmacol; 2015 Feb; 67(2):209-14. PubMed ID: 25557692
[TBL] [Abstract][Full Text] [Related]
2. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
3. Variability of plasma anti-Xa activities with different lots of enoxaparin.
Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
Ann Pharmacother; 2004 Apr; 38(4):563-8. PubMed ID: 14982983
[TBL] [Abstract][Full Text] [Related]
4. Anti-Xa activity after enoxaparin prophylaxis in hospitalized patients weighing less than fifty-five kilograms.
Rojas L; Aizman A; Ernst D; Acuña MP; Moya P; Mellado R; Cerda J
Thromb Res; 2013; 132(6):761-4. PubMed ID: 24521789
[TBL] [Abstract][Full Text] [Related]
5. Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
Corder A; Held K; Oschman A
Pediatr Blood Cancer; 2014 Jun; 61(6):1063-7. PubMed ID: 24375987
[TBL] [Abstract][Full Text] [Related]
6. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.
Ma JM; Jackevicius CA; Yeo E
Ann Pharmacother; 2004 Oct; 38(10):1576-81. PubMed ID: 15328396
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins.
Young E; Cosmi B; Weitz J; Hirsh J
Thromb Haemost; 1993 Oct; 70(4):625-30. PubMed ID: 8115988
[TBL] [Abstract][Full Text] [Related]
8. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.
Azizi M; Veyssier-Belot C; Alhenc-Gelas M; Chatellier G; Billaud-Mesguish E; Fiessinger JN; Aiach M
Br J Clin Pharmacol; 1995 Dec; 40(6):577-84. PubMed ID: 8703665
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays.
Harris LF; O'Brien A; Castro-López V; O'Donnell JS; Killard AJ
Thromb Res; 2011 Dec; 128(6):e166-70. PubMed ID: 21872908
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study.
Klingel R; Schwarting A; Lotz J; Eckert M; Hohmann V; Hafner G
Kidney Blood Press Res; 2004; 27(4):211-7. PubMed ID: 15273423
[TBL] [Abstract][Full Text] [Related]
11. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D
Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498
[TBL] [Abstract][Full Text] [Related]
12. Peak plasma anti-Xa levels after first and third doses of enoxaparin in women receiving weight-based thromboprophylaxis following caesarean section: a prospective cohort study.
Hiscock RJ; Casey E; Simmons SW; Walker SP; Newell PA
Int J Obstet Anesth; 2013 Nov; 22(4):280-8. PubMed ID: 23958275
[TBL] [Abstract][Full Text] [Related]
13. Stability of plasma anti-Xa activity in low-molecular-weight heparin monitoring.
Rojnuckarin P; Akkawat B; Juntiang J
Clin Appl Thromb Hemost; 2010 Jun; 16(3):313-7. PubMed ID: 19520682
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients.
Haas CE; Nelsen JL; Raghavendran K; Mihalko W; Beres J; Ma Q; Forrest A
J Trauma; 2005 Dec; 59(6):1336-43; discussion 1343-4. PubMed ID: 16394906
[TBL] [Abstract][Full Text] [Related]
15. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
[TBL] [Abstract][Full Text] [Related]
16. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory.
Marmur JD; Lakhani M; El Rouby S; Cavusoglu E
J Invasive Cardiol; 2008 Sep; 20(9):449-54. PubMed ID: 18762674
[TBL] [Abstract][Full Text] [Related]
17. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin.
Ip BK; Thomson AR; Moriarty HT
Pathology; 2001 Aug; 33(3):347-52. PubMed ID: 11523938
[TBL] [Abstract][Full Text] [Related]
19. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability.
Kitchen S; Iampietro R; Woolley AM; Preston FE
Thromb Haemost; 1999 Oct; 82(4):1289-93. PubMed ID: 10544915
[TBL] [Abstract][Full Text] [Related]
20. Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin.
Ramos-Esquivel A; Salazar-Sánchez L
Thromb Res; 2013 Oct; 132(4):433-6. PubMed ID: 24050826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
